Satellos Bioscience Inc. (MSLE)

NASDAQ • Market Data in USD, Fundamentals in CAD

$115.00

-$1.03

-0.88%

Last Update: 18 Jul 2026, 17:39

$1.10bn

Market Cap

-93.85

P/E Ratio (TTM)

—

Forward Dividend Yield

$80.69-$152.61

52 Week Range

MSLE Stock Price Chart

Explore Satellos Bioscience Inc. interactive price chart. Choose custom timeframes to analyze MSLE price movements and trends.

MSLE Company Profile

Discover essential business fundamentals and corporate details for Satellos Bioscience Inc. (MSLE) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

IPO Date

3 Aug 2012

Employees

18.00

Website

https://satellos.com

CEO

Frank Gleeson

Description

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

MSLE Financial Timeline

Browse a chronological timeline of Satellos Bioscience Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 12 Aug 2026

EPS estimate is -$0.51.

Earnings released on 14 May 2026

EPS came in at -$0.53 falling short of the estimated -$0.51 by -3.92%.

Earnings released on 27 Mar 2026

EPS came in at -$0.47 falling short of the estimated -$0.36 by -30.56%.

Stock split effective on 30 Jan 2026

Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 14 Nov 2025

EPS came in at -$0.36 falling short of the estimated -$0.33 by -11.14%.

MSLE Stock Performance

Access detailed MSLE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.